January 26, 2026 – Talk Bio

Rare Disease Vouchers Caught in Political Abyss: Recent Updates on Reauthorization Efforts

2 days ago talkbio0Tagged Beak, Bipartisan Support, Chance Act, Congress reauthorization, Infrequent, Mikaela Naylon Give Kids a, Pediatric Disorder, Priority Review Voucher, PRV, spending, United States Food and Drug Administration

Rare Pediatric Disease PRV; Mikaela Naylon Give Kids a Chance Act; Congress reauthorization; FDA priority review voucher; bipartisan support; spending bill

Revolution Medicines Rejects Merck’s Acquisition Bid, Stands Firm on Valuation Amid Ongoing Interest

2 days ago talkbio0Tagged acquisition talks, daraxonrasib, M&A, Merck, RAS, RAS inhibitors, Revolution Medicines

Revolution Medicines; Merck; acquisition talks; RAS inhibitors; daraxonrasib; biotech M&A

Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 for Elevated Lp(a)

2 days ago talkbio0Tagged Argo Biopharma, BW-20829, Cardiovascular Diseases, Lp(a ), Novartis, RNA, Small Interfering

Argo Biopharma; BW-20829; Phase 2b trial; siRNA; Lp(a); Novartis; cardiovascular disease